ArticleScientific reports2025
Probiotic potential of ginseng derived Lacticaseibacillus rhamnosus strains with hypocholesterolemic, antioxidant and antibacterial activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lacticaseibacillus Casei KGC1201 Isolated from Panax Ginseng Mitigates Dextran Sulfate Sodium-Induced Colitis by Modulating the Gut Environment.Probiotics and antimicrobial proteins · 2026Article
- Isolation and identification of lactic acid bacteria from ginseng sprouts and research on their probiotic, anti-inflammatory, and anti-cancer activity.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain one of the leading causes of mortality among adults worldwide, with elevated blood lipid levels serving as a key modifiable risk factor. This study aimed to investigate the probiotic potential of lactic acid bacteria (LAB) isolated from ginseng sprouts (Panax ginseng Meyer) cultivated under smart-farming conditions, with a particular emphasis on their cholesterol-lowering properties. Out of 485 isolates, five strains of Lacticaseibacillus rhamnosus were selected based on superior in vitro performance and identified through 16 S rRNA sequencing and phylogenetic analysis. The selected strains demonstrated high tolerance to simulated gastrointestinal conditions (pH 3.0, 0.3% bile salts), with survival rates ranging from 98 to 99%. In addition, they exhibited robust antibacterial activity, notable antioxidant capacity and antibiotic susceptibility to erythromycin and clindamycin, while showed resistance to tetracycline and vancomycin. The selected bacterial strains reduced cholesterol levels by 30% as compared to the reference strain Lacticaseibacillus rhamnosus GG. Moreover, the formation of white precipitates around the bacterial colonies grown on media supplemented with 0.5% (w/v) TDCA and 0.37 g/L CaCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.